INMUNE BIO INC. Deferred Tax Assets, Operating Loss Carryforwards, Foreign
INMUNE BIO INC. (INMB) had Deferred Tax Assets, Operating Loss Carryforwards, Foreign of $9.82 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $9.82M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $8.22M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $5.96M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $4.31M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Foreign | Deferred Tax Assets, Operating Loss Carryforwards, Foreign as first filed |
|---|---|---|
| 2025-12-31 | $9.82M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $8.22M 10-K · filed 2026-03-30 | |
| 2023-12-31 | $5.96M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $4.31M 10-K · filed 2024-03-28 | |
| 2021-12-31 | $2.16M 10-K · filed 2023-03-02 | |
| 2020-12-31 | $782.00K 10-K · filed 2022-03-03 | $781.16K 10-K · filed 2021-03-04 |
| 2019-12-31 | $378.88K 10-K · filed 2021-03-04 | |
| 2018-12-31 | $340.00K 10-K · filed 2020-03-11 | |
| 2017-12-31 | $109.64K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |